Cost effectiveness of exome and chromosomal microarray analysis in cases of severe central nervous system structural anomalies

OBJECTIVE: The central nervous system (CNS) is affected in 9% of fetal malformations but accounts for as much as one-third of all pregnancy terminations due to fetal anomaly. When applying chromosomal microarray (CMA) to the diagnosis of fetal CNS anomalies, the estimated diagnostic yield remains low. Recent study demonstrated that, in fetuses with major CNS anomalies, exome sequencing (ES) had an additional diagnostic yield of 44% over the 10% provided by CMA. We aimed to determine the cost effectiveness of the added value of ES in major CNS structural anomalies. METHODS: We modeled costs, utility, and quality-adjusted life-years (QALYs) for CMA versus CMA + ES in prenatal testing. Two strategies were compared using the Markovian process decision analysis model: (1) CMA only, abnormal result culminating in termination of pregnancy (TOP); (2) ES after a negative CMA, where for positive result a TOP is conducted. The outcomes included health quality of life after TOP or having a disabled child, the costs of the CMA test, the ES test, and the health expenses of a disabled child. The time horizon of the model was 20 years. Sensitivity analysis including probabilistic sensitivity analysis of all parameters was conducted. RESULTS: In the base-case model, the total expected cost per pregnancy was $US 91 059 for the CMA-alone strategy (driven largely by the expected long-term cost of raising a child with an undiagnosed disability) and $US 3101 for the CMA + ES strategy. The QALYs with a time horizon of 20 years were 11.84 and 13.84 for CMA and CMA + ES strategies, respectively, so CMA + ES dominated CMA alone (higher QALY value and cost saving). Sensitivity analysis revealed that the results were robust, and CMA + ES dominated the CMA with cost savings for all sensitivity analysis. CONCLUSIONS: We suggest that ES has the potential to be cost effective and should be considered as a first-tier test in the prenatal diagnosis of major CNS anomalies. The substantial increase in diagnostic yield offered by ES not only provides valuable information for the current pregnancy but also holds significant relevance for future pregnancies. These findings are pivotal in facilitating timely and evidence-based decision-making.

Authors

Institutions

Publication Details

Journal
International Journal of Gynecology & Obstetrics
Published
2026-11-20
DOI
https://doi.org/10.1002/ijgo.71480
Primary Topic
Prenatal Screening and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost effectiveness of exome and chromosomal microarray analysis in cases of severe central nervous system structural anomalies

Yariv Yogev, Michal Rosenberg-Friedman, Adi Reches, Sharon Maslovitz et al.
International Journal of Gynecology & Obstetrics
Prenatal Screening and Diagnostics
article

Cost effectiveness of exome and chromosomal microarray analysis in cases of severe central nervous system structural anomalies

Yariv Yogev, Michal Rosenberg-Friedman, Adi Reches, Sharon Maslovitz, Lee Reicher, Moshe Leshno, Omri Dominsky
article en

Abstract

OBJECTIVE: The central nervous system (CNS) is affected in 9% of fetal malformations but accounts for as much as one-third of all pregnancy terminations due to fetal anomaly. When applying chromosomal microarray (CMA) to the diagnosis of fetal CNS anomalies, the estimated diagnostic yield remains low. Recent study demonstrated that, in fetuses with major CNS anomalies, exome sequencing (ES) had an additional diagnostic yield of 44% over the 10% provided by CMA. We aimed to determine the cost effectiveness of the added value of ES in major CNS structural anomalies. METHODS: We modeled costs, utility, and quality-adjusted life-years (QALYs) for CMA versus CMA + ES in prenatal testing. Two strategies were compared using the Markovian process decision analysis model: (1) CMA only, abnormal result culminating in termination of pregnancy (TOP); (2) ES after a negative CMA, where for positive result a TOP is conducted. The outcomes included health quality of life after TOP or having a disabled child, the costs of the CMA test, the ES test, and the health expenses of a disabled child. The time horizon of the model was 20 years. Sensitivity analysis including probabilistic sensitivity analysis of all parameters was conducted. RESULTS: In the base-case model, the total expected cost per pregnancy was $US 91 059 for the CMA-alone strategy (driven largely by the expected long-term cost of raising a child with an undiagnosed disability) and $US 3101 for the CMA + ES strategy. The QALYs with a time horizon of 20 years were 11.84 and 13.84 for CMA and CMA + ES strategies, respectively, so CMA + ES dominated CMA alone (higher QALY value and cost saving). Sensitivity analysis revealed that the results were robust, and CMA + ES dominated the CMA with cost savings for all sensitivity analysis. CONCLUSIONS: We suggest that ES has the potential to be cost effective and should be considered as a first-tier test in the prenatal diagnosis of major CNS anomalies. The substantial increase in diagnostic yield offered by ES not only provides valuable information for the current pregnancy but also holds significant relevance for future pregnancies. These findings are pivotal in facilitating timely and evidence-based decision-making.

International Journal of Gynecology & Obstetrics
Tel Aviv University (IL), Tel Aviv Sourasky Medical Center (IL), Weizmann Institute of Science (IL)
Prenatal Screening and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon